Table 4.

Potentially clinically important laboratory values through week 112

Parameter	Threshold	Patients, n (%)
		Upadacitinib 15 mg (N = 133)a	Upadacitinib 30 mg (N = 136)a
Hemoglobin, g/L	< 80 g/L	0	0
Lymphocytes, 109/L	< 0.5 × 109/L	1 (0.8)	3 (2.2)
Neutrophils, 109/L	< 1.0 × 109/L	2 (1.5)	3 (2.2)
Platelets, 109/L	< 50 × 109/L	0	0
ALT, U/L	> 5.0 × ULN	2 (1.5)	1 (0.7)
Alkaline phosphatase, U/L	> 5.0 × ULN	0	0
AST, U/L	> 5.0 × ULN	1 (0.8)	0
Creatinine, µmol/L	> 3.0 × ULN	0	0
CPK, U/L	> 5.0 × ULN	4 (3.0)	9 (6.6)

ALT alanine aminotransferase, AST aspartate aminotransferase, CPK creatine phosphokinase, ULN upper limit of normal

^aAll patients received concomitant topical corticosteroids from baseline to week 16. After week 16, the use of concomitant topical corticosteroids was no longer required and was administered per investigator discretion